Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference

Jun 04, 2022 1:15 PM CDT to Jun 04, 2022 4:15 PM CDT

Details of this virtual poster presentation at ASCO 2022 are as follows:

Title: Efficacy of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer in phase 3 PRIME study: A subgroup analysis by response to first-line platinum-based chemotherapy.

Abstract number: 5551

Abstract link:

Session Title: Gynecologic Cancer

Session Date and Time: Saturday, June 4, 2022, 1:15 PM-4:15 PM CDT

Presenter: Dr. Rutie Yin, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, China